The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- UMC Utrecht
- Study ID
- NCT04075305
- Status
- Recruiting
Conditions
- Bladder Cancer
- Bladder Neoplasm
- Brain Cancer
- Brain Tumor
- Breast Cancer
- Breast Tumor
- Esophageal Cancer
- Esophageal Neoplasm
- Esophageal Tumor
- Esophagus Cancer
- Esophagus Neoplasm
- Esophagus Tumor
- Gynecologic Cancer
- Gynecologic Tumor
- Head and Neck Cancer
- Head and Neck Neoplasms
- Head and Neck Tumor
- Liver Cancer
- Liver Metastases
- Liver Neoplasms
- Lung Cancer
- Lung Neoplasm
- Lung Tumor
- Neoplasms
- Oligometastases
- Oncology
- Pancreatic Cancer
- Pancreatic Neoplasms
- Pancreatic Tumor
- Prostate Cancer
- Prostate Neoplasm
- Prostate Tumor
- Quality of Life
- Radiation Toxicity
- Rectal Cancer
- Rectal Neoplasms
- Rectal Tumor
- Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Radiation therapy — RADIATIONRadiation therapy on the CE marked and FDA approved MR-Linac
Study Details
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Key Dates
- Start date
- Feb 1, 2019
- Status verified
- Jan 2026
- Primary completion
- Feb 1, 2030
- Completion
- Aug 1, 2030
Study Design
- Enrollment
- 8,000 participants (estimated)
Arms
- Arm: Brain cancer
- Arm: Lung cancer
- Arm: Esophageal cancer
- Arm: Breast Cancer
- Arm: Head and Neck Cancer
- Arm: Pancreatic cancer
- Arm: Gynecological cancer
- Arm: Rectal cancer
- Arm: Prostate cancer
- Arm: Bladder cancer
- Arm: Oligometastases
- Arm: Liver cancer
- Arm: Other types of cancer
Primary Outcome Measure
Progression-free Survival [ Time Frame: 3 months after MR-Linac treatment ]
Central Contacts
- Tessa LeerT +31 (0)88 75 63707
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | Tom Colonias |
| Md Anderson Cancer Center | Houston | Texas | 77030 | |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | William A Hall |
Find similar trials in Pittsburgh, PA
By condition
By specialty
Related Studies
- Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of LifeRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Esophageal Cancer Risk RegistryRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Detection of Genetic Markers of Lung CancerRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Genetic Determinants of Barrett's Esophagus and Esophageal AdenocarcinomaRecruiting · Case Western Reserve University · Baltimore, Maryland